Clinical significance of pretreatment De Ritis ratio in renal cell carcinoma

Abstract

Aims: This study aimed to investigate the relationship between pretreatment De Ritis ratio and Fuhrman nuclear grade and tumor stage in renal cell carcinoma (RCC). Methods: The data of 288 patients treated for RCC were analyzed. The De Ritis ratio was evaluated in patients classified by Fuhrman nuclear grade and tumor stage. The De Ritis ratio between groups was compared using Levene’s test. Results: A total of 145 patients (50.3%) were women female. Their mean age, aspartate aminotransferase, alanine aminotransferase values, and De Ritis ratio were as follows, respectively: 60.32±12.65 years, 20.55±11.54 IU/L, 17.4±10.87 IU/L, and 1.34±0.75. The De Ritis ratio was 1.12±0.44 in the low stage group and 2.01±1.05 in the high stage group. According to the Fuhrman nuclear grading, the De Ritis ratio was 1.15±0.43 in the low grade group and 1.70±1.14 in the high grade group. There was a statisticallysignificant difference between the groups (p<0.001). Conclusion: The present study showed high preoperative De Ritis ratio is significantly correlated with high tumor stage and Fuhrman nuclear grade in RCC.

Keywords

• De Ritis ratio
• transaminases
• renal cell carcinoma
• furhman grade

References

1. 1. Kölükçü E, Kılıç Ş, Atılgan D, et al. Clinical relevance of preoperative neutrophil to lymphocyte and platelet to lymphocyte ratio in renal cell carcinoma. J Urol Surg. 2018; 5(4):189-193.
2. 2. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51(6):1502-1510.
3. 3. Urakci Z, Karhan O, Ebinc S, et al. A renal cell carcinoma case presented with spinal cord compression. Int Arch Med Res. 2018; 10(1):15-20.
4. 4. Kölükçü E, Beyhan M, Aşcı M, et al. Metastatic renal cell carcinoma diagnosed by humerus metastasis: case report. J Health Sci Med. 2019;2(2):68-71.
5. 5. Xing T, He H. Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res. 2016;28(1):80-91.
6. 6. İzol V, Soyupak B. Surgery in metastatic renal cell carcinoma. Bull Urooncol. 2011;10(1):36-40.
7. 7. Canat L, Ataly HA, Agalarov S, Alkan İ, Alturende F. The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma. Int Braz J Urol. 2018;44(2):288-295.
8. 8. Fırat SN, Taşkaldıran I, Kuşkonmaz ŞM, Culha C. AST/ALT (De Ritis) ratio in early stage ifferentiated thyroid cancer. KOU Sağ Bil Derg. 2022;8(2):125-128.

9. 9. Şahin Y, Yılmaz M, Hacıbey İ, et al. Is there any correlation between De Ritis ratio and prostate cancer in males who underwent transrectal prostate biopsy? Bağcılar Med Bull. 2021; 6(1):66-72.
10. 10. Ishihara H, Kondo T, Yoshida K, et al. Evaluation of preoperative aspartate transaminase/alanine transaminase ratio as an independent predictive biomarker in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy: a propensity score matching study. Clin Genitourin Cancer. 2017; 15(5):598-604.
11. 11. Bezan A, Mrsic E, Krieger D, et al. The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J Urol. 2015; 194(1):30-35.
12. 12. Wang H, Fang K, Zhang J, et al. The signifcance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients. Int Urol Nephrol. 2017;49(8):1391-1398.
13. 13. Yuk HD, Jeong CW, Kwak C, Kim HH, Ku JH. De Ritis ratio (aspartate transaminase/alanine transaminase) as a significant prognostic factor in patients undergoing radical cystectomy with bladder urothelial carcinoma: a propensity score-matched study. Dis Markers. 2019:2019:6702964.
14. 14. Swami U, Nussenzveig RH, Haaland B, Agarwal N. Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. Ann Transl Med. 2019;7(1):S18.
15. 15. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655-663.
16. 16. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49(5):798-805.
17. 17. Göğüs Ç. Lokalize, metastatik ve nüks böbrek tümörlerinde cerrahi nereye kadar? Bull Urooncol. 2008;7(4):17-25.
18. 18. Gül Ü, Yaycıoğlu Ö. Prognostic factors in renal cancer and prediction models. Bull Urooncol. 2011;10(3):5-10.
19. 19. Zheng BS, Wang SD, Zhang JY, Ge CG. Incidence, Prognostic factors, and survival of patients with renal cancer: a population-based study. J Invest Surg. 2023;36(1):2197506.
20. 20. Ali RM, Muhealdeen DN, Fakhralddin SS, et al. Prognostic factors in renal cell carcinoma: a single-center study. Mol Clin Oncol. 2023;19(3):66.
21. 21. Solmaz ÖA, Yekeler H. The relationship of Ki-67 proliferation index, p53 expression, AgNOR number and prognostic factors in kidney’s renal cell carcinomas with histopathological type and grading. Fırat Tıp Derg. 2010;15(1):34-39.
22. 22. Tsai CH, Hsieh TM, Hsu SY, Hsieh CH. A high De Ritis ratio is associated with mortality in adult trauma patients. Risk Manag Healthc Policy. 2023:16:879-887.
23. 23. Laukhtina E, Pradere B, Andrea DD, et al. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2020;38(12):936-936.
24. 24. Lee H, Lee SE, Byun SS, Kim HH, Kwak C, Hong SK. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study. BJU Int. 2017;119(2):261-267.
25. 25. Ikeda T, Ishihara H, Takagi T, et al. The De Ritis (aspartate transaminase/alanine transaminase) ratio as a prognosticator in patients with end-stage renal disease-associated renal cell carcinoma. Clin Genitourin Cancer. 2020;18(3):236-240.
26. 26. Kang M, Yu J, Sung HH, et al. Prognostic impact of the pretreatment aspartate transaminase/ alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. Int J Urol. 2018;25(6):596-603.
27. 27. Batur AF, Aydogan MF, Korez MK, et al. Prognostic value of De Ritis ratio (aspartate aminotransaminase/alanine aminotransaminase) and Systemic inflammatory markers in patients with non-metastatic clear cell renal cell carcinoma. Osmangazi J Med. 2021;43(6):662-672.
28. 28. Janisch F, Klotzbücher T, Marks P, et al. Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. World J Urol. 2021;39(8):2977-2985.